copper tripeptide-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-28 and is reviewed periodically as new material appears.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
| Property | Value | Notes |
|---|---|---|
| Sequence | Gly-His-Lys | Three amino acids; histidine supplies the main copper-binding nitrogen |
| Bound metal | Copper(II) | Coordination is described as square-planar around the metal centre |
| Appearance | Blue to violet solid | Colour originates from copper d-d electronic transitions |
| Solubility class | Freely soluble in water | Aqueous solutions are often slightly acidic |
| Common synonyms | Copper tripeptide, Cu-GHK | Ingredient lists may say only 'copper peptide' without giving the sequence |
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The upper gastrointestinal tract consists of the mouth, pharynx, esophagus, stomach, and duodenum. The exact demarcation between the upper and lower tracts is the suspensory muscle of the duodenum. This differentiates the embryonic borders between the foregut and midgut, and is also the division commonly used by clinicians to describe gastrointestinal bleeding as being of either "upper" or "lower" origin. Upon dissection, the duodenum may appear to be a unified organ, but it is divided into four segments based on function, location, and internal anatomy. The four segments of the duodenum are as follows (starting at the stomach, and moving toward the jejunum): bulb, descending, horizontal, and ascending. The suspensory muscle of the duodenum suspends the superior border of the ascending duodenum from the diaphragm, and serves as an important anatomical landmark showing the formal division between the duodenum and the jejunum, the first and second parts of the small intestine, respectively. This is a thin muscle which is derived from the embryonic mesoderm.
Under mild reduction, the naturally occurred (-)-ptaquilosin 11 was obtained. The Yamada's synthesis proceeded in 20 steps with an overall yield of 2.9%. Similarly, the unnatural (+)-enantiomer of ptaquilosin was synthesized from the diastereomer of 2.
The product of this reaction, acetyl-CoA, is the starting point for the citric acid cycle. Acetyl-CoA may also be obtained from the oxidation of fatty acids. Below is a schematic outline of the cycle:
At the meeting to close the deal, one of the bankers recorded, "Michael thought he was President of the Oxford Union again, and entered into a grand oration and bored everyone stiff". In 1971 Heseltine placed his shares in a trust controlled by his ministerial boss Peter Walker and by his solicitor Charles Corman. Haymarket's pretax profits were £453,000 in 1971 and £704,000 in 1972. Haymarket was due to be floated as a public company in the autumn of 1973, although this was cancelled because of the rise in the oil price, which reduced the profitability of the publishing industry. They thus avoided the stock market crash which followed. The company remains privately owned to this day. Heseltine acted as a consultant to Haymarket during his period out of government office between 1974 and 1979. His role was to bring in new publishing ideas. He believed he increased performance, although Robert Heller later recorded that he did very little, for he was too busy as a member of the Shadow Cabinet. He worked from an office at Haymarket, near Regent Street, rather than in the House of Commons. Under the management of Masters and Tindall, Haymarket continued to grow. By 1976 it was making annual profits of round £1.75m. In 1976–1977 Heseltine, Masters, Tindall and the Finance Director David Fraser bought out the consortium's 40% share, using money borrowed from them, giving Heseltine and his family over 50% control of Haymarket. Heseltine had taken out large personal loans both to increase his stake in the company and to buy his country mansion Thenford House.
== P == Pier Paolo Pandolfi (b. 1963). Italian geneticist and molecular biologist at the Desert Research Institute, Reno, known for work on pseudogenes. Jakub Karol Parnas (1884–1949). Polish-Soviet biochemist at the University of Lviv, who discovered (with Gustav Embden and Otto Fritz Meyerhof), the glycolytic pathway. Linus Pauling (1901–1994). American chemist and biochemist at Caltech, known for many advances in chemistry, including the α-helical structure of proteins. Nobel Prize in Chemistry (1954). Louis Pasteur FRS (foreign associate) (1822–1895). French biologist, microbiologist and chemist at the Pasteur Institute (Paris), who made many contributions to microbiology, stereochemistry and medicine, including the first vaccines for rabies and anthrax. Natl. Acad. Sci. USA (foreign associate). Arthur Peacocke (1924–2006). British Anglican theologian and biochemist at the University of Oxford. Max Perutz FRS (1914–2002). Austrian-British molecular biologist and X-ray crystallographer at Cambridge University, who solved the crystal structure of haemoglobin. Nobel Prize in Chemistry (1962). Samuel Victor Perry FRS (1918–2009). British biochemist at the University of Birmingham, pioneer in the biochemistry of muscle. Gösta Pettersson (b. 1937). Swedish biochemist at the University of Lund, expert on enzyme kinetics. Antoinette Pirie (1905–1991), British biochemist, ophthalmologist, and educator. Norman Wingate Pirie FRS (1907–1997), British biochemist and virologist. Rosalind Pitt-Rivers (1907–1990).
Sources: en.wikipedia.org
It is common in particle physics to use eV/c2 as a unit of mass. Here, eV (electronvolt) is a unit of energy (the kinetic energy of an electron accelerated over one volt, 1.6×10−19 J), and c is the speed of light in vacuum. Energy and mass are related through E = mc2. This definition is useful for a linear particle accelerator when accelerating electrons.
==== Employees and DuPont exposed community ==== In 2010, the three members of the C8 Science Panel published a review of the epidemiological evidence on PFOA exposure in Environmental Health Perspectives. Insufficient evidence exists to conclude PFOA causes adverse health effects in humans, but consistent evidence exists on associations with higher cholesterol and uric acid. Whether or not these potential effects result in an increase in cardiovascular disease is unknown. Further data on the 69,030 member cohort that is being studied by the panel is scheduled for release through 2012. A 2011 epidemiological study demonstrated "probable link" between PFOA and kidney cancer, testicular cancer, thyroid disease, high cholesterol, pre-eclampsia and ulcerative colitis. Facial birth defects, an effect observed in rat offspring, occurred with the children of two out of seven female DuPont employees from the Washington Works facility from 1979 to 1981. Bucky Bailey is one of the affected individuals; DuPont, however, does not accept any liability from the toxicity of PFOA. While 3M sent DuPont results from a study that showed birth defects to rats administered PFOA and DuPont moved the women out of the Teflon production unit, subsequent animal testing led DuPont to conclude there was no reproductive risk to women, and they were returned to the production unit. However, data released in March 2009 on the community around DuPont's Washington Works plant showed "a modest, imprecise indication of an elevation in risk ... above the 90th percentile ...
=== Error-prone replication bypass === There is increasing evidence that the majority of spontaneously arising mutations are due to error-prone replication (translesion synthesis) past DNA damage in the template strand. In mice, the majority of mutations are caused by translesion synthesis. Likewise, in yeast, Kunz et al. found that more than 60% of the spontaneous single base pair substitutions and deletions were caused by translesion synthesis.
The second-generation Familia was manufactured in South Korea by Kia Motors at their first integrated automobile manufacturing facility, the Sohari Plant in Gwangmyeong. Production commenced in 1973 in the form of the Brisa B-1000 pickup; the passenger model (originally as the "Brisa S-1000") was added in October 1974. The Brisa nameplate comes from the Spanish and Portuguese word for "breeze". It was originally equipped with a 62 PS (46 kW) 1.0-litre Mazda engine, and a bigger 1.3-litre engine was later added to the line up. Production of the Brisa was halted in 1981, as the military dictator Chun Doo-hwan enforced industry consolidation, which required Kia to abandon passenger cars and concentrate solely on light trucks. The original version of the Brisa received a slightly different front end from the original Familia, featuring twin headlights. Later, single headlights were used. In total, 31,017 Brisa passenger cars were built. Including the pickups increases the totals to 75,987, of which a total of 1,526 were exported. Exports, Kia's first, began with a shipment of 31 Brisa B-1000 pickups to Qatar in 1975. The Brisa (along with the pickup model, typically called "Master" in export) was also exported to Colombia and Greece. The model appeared prominently in the 2017 South Korean film A Taxi Driver, which told the true story of a German reporter and a South Korean taxi driver who became caught up in Chun's harsh response to the Gwangju Uprising in 1980.
=== Charges === On January 7th, 2010, U.S. Immigration and Customs Enforcement (ICE) agents authorized by a grand jury with a search and arrest warrant entered the residence of Mahmoud Reza Banki in New York City and arrested him. He was arraigned before Judge John F. Keenan on an indictment charging him with three counts: 1. Conspiracy to violate the U.S.-imposed Iran sanctions and conspiracy to run an unlicensed money transmittal system, 2. Violation of the Iran sanctions, and 3. Running of an unlicensed money transmittal business. The indictment accused Banki of receiving $4.7 million in violation of the Iran sanctions. Prosecutors filed a superseding indictment later changing the amount to $3.4 million and adding two false statement charges to the three initial charges.
Sources: en.wikipedia.org
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).
The free tripeptide and its copper complex have been measured in human plasma, saliva, urine and some tissue extracts. Reported concentrations vary widely between studies, and the role of the complex in normal physiology remains partly unresolved.
The plain peptide lacks the metal, so its charge, colour and binding behaviour differ. The copper complex is blue and carries a bound copper ion, while the metal-free form is colourless and has different solution chemistry.
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.